Navigation Links
Sinovac Closes $9.75 Million Private Placement
Date:2/4/2008

BEIJING, Feb. 4 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the completion of a $9.75 million private placement of its common shares.

On January 22, 2008, Sinovac entered into a share purchase agreement with Sansar Capital Management, L.L.C. The private placement with Sansar closed on February 1, 2008. Sinovac received approximately $9.75 million in gross proceeds from the sale of 2,500,000 of its common shares at a purchase price of $3.90 per share. Sinovac plans to use the funds for general corporate purposes and working capital, including acquisition opportunities that may arise from time to time.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, and Japanese encephalitis. Additional information about Sinovac is available on its website, http://www.sinovac.com. To be added to our distri
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
5. Genmab Discloses Target and Development Plans for HuMax-Inflam
6. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
7. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
8. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
9. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
10. BioVex Closes Second Round of Series E Financing
11. Pharmaxis Closes Share Purchase Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 •    First of ... Certified for sustainability ,     New facility will help ... , Syngenta unveiled its new crop ... the company’s RTP Innovation Center. The first of its ... to simulate any agricultural climate and precisely measure plant ...
(Date:5/17/2013)... 2013  Insero Health, Inc., a company developing natural ... related neurological disorders, is today reporting top-line results from ... in patients with drug-resistant epilepsy.  The data are being ... Xll meeting by Dr. Steven Schachter ... Scientific Advisory Board.  In this study, INS001 appeared safe ...
(Date:5/17/2013)... CA (PRWEB) May 17, 2013 IAC Industries ... Technologies, a start up laboratory needing to set up and ... moving to a larger facility within a year’s time. How ... knowledge that the laboratory is temporary? What is efficient and ... Series modular workstations from IAC Industries. The planners at DisperSol ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 In late 2012, ... to speak to doctors in China about Appearance Medicine ... NZ, this was her first trip to lecture in China, ... visited Guangzhou and Fuzhou, home to 12 and 7 million ... is very high at this point in time. As Dr. ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... MONTVALE, N.J., June 26 Barr Pharmaceuticals,Inc. (NYSE: ... Court for Delaware has,ruled in favor of its ... patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in,connection ... 0.5mg, 1mg & 1.5mg., In his ruling, ...
... will be home to the,world,s first industrial scale ... City has signed a 25-year agreement with GreenField,Ethanol, ... biofuels,technology company., The $70 million biofuels facility ... year and reduce Alberta,s carbon dioxide (CO2),footprint by ...
... Balance Business Benefits with ... Environmental Responsibility, FALLS CHURCH, Va., and ATLANTA, ... constrained by the,inability to justify cost of implementation, according to "The ... CSC ), Manhattan,Associates Inc. (Nasdaq: MANH ), IBM and ...
Cached Biology Technology:Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge 2Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge 3Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge 4Edmonton to be site of world's first industrial scale municipal waste-to-ethanol facility 2Edmonton to be site of world's first industrial scale municipal waste-to-ethanol facility 3Edmonton to be site of world's first industrial scale municipal waste-to-ethanol facility 4Edmonton to be site of world's first industrial scale municipal waste-to-ethanol facility 5Study Reveals Greatest Barrier to Green Supply Chain Initiatives 2Study Reveals Greatest Barrier to Green Supply Chain Initiatives 3
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) ... diet and lifestyle. , Individuals suffering from ... strength, fatigue and poor quality of life. These ... remission. A randomized, double blind, placebo-controlled study found ... corresponded to significant relief of these symptoms. ...
(Date:5/17/2013)... University of New Jersey, and City University of New ... TM that effectively clears organisms to be viewed ... chloral hydrate, which is one of the few high-quality ... by the Drug Enforcement Administration (DEA) due to its ... agents, are vital for viewing organisms under a microscope. ...
(Date:5/17/2013)... Efficient and Sustainable Global Logistics Operations) is aiming to ... efficiency of intermodal loading systems and the boosting of ... European organisations with experience in the logistics sector and ... 17,000,000 and a duration of three and a half ... the semantic components and ontologies shared by the users, ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3New logistics services that will cut energy consumption and CO2 emissions 2
... Humans have an innate defence system against deadly bacteria. However, ... the body is not yet known. To date, B. ... elude medics. It can remain hidden in the human body ... The bacteria can suddenly become activated and spread throughout the ...
... LUNG TRANSPLANTATION , (Tuesday, October 28, 10:30 AM ... arrhythmias, including atrial fibrillation. Researchers from Baylor College ... all lung transplant recipients in 2006 and 2007. ... 38 percent developed arrhythmias within 30 days of ...
... published in the open access journal PLoS Biology, ... surprising result that the survival of juvenile salmon in ... of an extensive network of dams in one river system., ... dwellers such as sharks, sturgeon, tuna and sea turtles, and ...
Cached Biology News:New cardiology research presented at CHEST 2008 2New cardiology research presented at CHEST 2008 3New cardiology research presented at CHEST 2008 4Research challenges conventional notions about salmon survival 2
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: